Disc Medicine (IRON) Stock Price, Quote, News & History | Benzinga

SPY767.78+0.59%QQQ718.53+1.23%BTC/USD—DIA519.25+0.03%GLD382.15+0.04%TLT80.13+0.10%

Disc Medicine Inc (IRON) Stock Price, Quote, News & History

IRONNASDAQ

Trade with Public

Trade with Public

$56.84

0.190.34%

Last update: Oct 19, 6:52 AM

$71.60

14.9526.39%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

-

Close

$56.84

Volume / Avg.

202.99K / 485.86K

Day Range

- - -

52 Wk Range

40.00 - 99.50

Market Cap

$2.75B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

60

Short Interest

22.08%

Days to Cover

12.79

Recent Disc Medicine, Inc. News

Stock Market Today: Dow Jones, S&P 500 Futures Rise as Scott Bessent Links September Inflation to 'Energy Shock' — RCAT, ESLT, STLD in Focus

U.S. stock futures were higher on Monday, as the Dow Jones, S&P 500 and Nasdaq 100 indices rose, following Friday's lower close.

Rishabh Mishra

Why XCF Global Shares Are Trading Higher By Around 65%; Here Are 20 Stocks Moving Premarket

XCF Global surged 64.9% premarket after completing a business combination and forecasting 2025 revenue of $120M-$130M and EBITDA of $70M-$75M.

Avi Kapoor

Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday

Analysts raised targets for RAPP, ALLR, UNP and ALVO; cut targets for NU, CLLS and JBHT, with several rating upgrades and downgrades.

Avi Kapoor

Disc Medicine Shares Polycythemia Vera Data, Outlines Late 2026 Trial Milestones

Disc Medicine says Phase 2 RESTORE-PV data shows DISC-3405 reduces phlebotomy needs and controls hematocrit in polycythemia vera patients.

Vandana Singh

FDA Delays Disc Medicine's Rare Disease Drug

Disc Medicine stock plunged after an FDA rejection of its rare disease drug but rebounded as investors weigh next steps.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-197.54M

Investing Cash Flow (TTM)

-93.42M

Financing Cash Flow (TTM)

262.30M

Free Cash Flow (TTM)

-197.58M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

-28.66M

Analyst Trends and Forecast

1

May

2

Jun

1

Aug

3

Sep

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.2

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$1.53B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

3.39

Earnings Yield % (TTM)

-11.58%

Earnings Yield % (FWD)

-11.37%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$16.78

Company Debt

Total Debt

$59.34M

LT Debt

$59.34M

LT Debt Issuance (TTM)

$29.98M

LT Debt Repayment (TTM)

-

Total Cash

$98.68M

Debt to Equity

0.09

Issuance of Debt (TTM)

$29.98M

Repayment of Debt (TTM)

-